“…In 2020, five markers of receptivity ( ITGβ1 [ 112 ], RAC1 [ 113 ], HOXA11 [ 111 ], ITGβ3 [ 112 , 114 ], and NOGGIN [ 111 ]) were compared between menstrual blood samples taken from women with RIF, versus fertile controls, revealing different patterns of expression. This observation led the authors to propose that aberrant eMSCs contribute to altered endometrial receptivity in women with RIF [ 115 ]. eMSCs from menstrual blood were isolated and characterised based on their morphology and behaviour, expression of specific surface markers (CD44, CD31, CD34, CD73, CD90, and CD105), and capacity to differentiate, all of which was based on the International Society for Cellular Therapy statement [ 115 , 116 ].…”